abstract |
The present invention provides succinate salts of 2-((4- (1-methyl-4- (pyridin-4-yl) -1H-pyrazol-3-yl) phenoxy) methyl) quinoline, and succinate salts. A method of treating central nervous system (CNS) disorders and other disorders in mammals, including humans, by administration to an animal. The present invention also relates to pharmaceutical compositions containing pharmaceutically acceptable carriers and succinate salts. |